Current Report Filing (8-k)
01 July 2016 - 11:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
July 1, 2016
|
OPKO Health, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-33528
|
75-2402409
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
4400 Biscayne Blvd., Miami, Florida
|
|
33137
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
(305) 575-4100
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On July 1, 2016, OPKO Health, Inc. (the Company) determined that its 3.0% Convertible Senior
Notes due 2033 (the Notes), of which $32.2 million is outstanding, continue to be convertible by
holders of such Notes through September 30, 2016. The Company has elected to satisfy its
conversion obligation under the Notes in shares of the Companys common stock. The conversion
right has been extended because the closing price per share of the Companys common stock has
exceeded $9.19, or 130% of the applicable conversion price of $7.07, for at least 20 of 30
consecutive trading days during the quarter ended June 30, 2016. The Company had previously
announced that this conversion right had been triggered during the quarters ended March 31, 2015,
June 30, 2015, September 30, 2015, December 31, 2015, and March 31, 2016. The Notes will continue
to be convertible until September 30, 2016, and may be convertible thereafter, if one or more of
the conversion conditions specified in the Indenture, dated as of January 30, 2013, by and between
the Company and Wells Fargo Bank N.A. (the Indenture), is satisfied during future measurement
periods. Pursuant to the Indenture, a holder who elects to convert the Notes will receive 141.4827
shares of the Companys common stock plus such number of additional shares as is applicable on the
conversion date per $1,000 principal amount of Notes based on the early conversion provisions in
the Indenture. A complete explanation of the conversion rights of holders of the Notes, as well as
the procedures required to convert the Notes, is set forth in the Indenture.
Wells Fargo Bank, National Association is the trustee for the holders of the Notes and the
conversion agent under the Indenture. Any questions relating to the mechanics of the conversion for
the Notes should be directed to Wells Fargo Bank National Association, Attn: Barry Somrock at
CMESCONVERSIONS@wellsfargo.com.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
OPKO Health, Inc.
|
|
|
|
|
|
July 1, 2016
|
|
By:
|
|
Adam Logal
|
|
|
|
|
|
|
|
|
|
Name: Adam Logal
|
|
|
|
|
Title: Senior Vice President,
|
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024